Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob M Rowe

Showing results (201-210 of 275) with videos related to

Pageof 28
Sort By:
Blood|October 13, 2006
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyAdele K Fielding, Susan M Richards, Rajesh Chopra, et al.
Blood|March 25, 2006
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trialMats Brune, Sylvie Castaigne, John Catalano, et al.
Nature Medicine|February 28, 2012
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALLGiusy Della Gatta, Teresa Palomero, Arianne Perez-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocolMarc R Mansour, Maria L Sulis, Veronique Duke, et al.
American Journal of Hematology|June 16, 2018
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experienceChezi Ganzel, Zhuoxin Sun, Larry D Cripe, et al.
Cancer Discovery|October 29, 2021
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic LeukemiaMarissa Rashkovan, Robert Albero, Francesca Gianni, et al.
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
American Journal of Hematology|October 9, 2019
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective studyYishai Ofran, Michal Hayun, Ronit Leiba, et al.
Haematologica|September 3, 2016
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemiaNicola Gökbuget, Hervè Dombret, Jose-Maria Ribera, et al.
Haematologica|November 24, 2018
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900Hugo F Fernandez, Zhuoxin Sun, Mark R Litzow, et al.
Pageof 28

Showing results (201-210 of 275) with videos related to

Sort By:
Pageof 28
Blood|October 13, 2006
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyAdele K Fielding, Susan M Richards, Rajesh Chopra, et al.
Blood|March 25, 2006
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trialMats Brune, Sylvie Castaigne, John Catalano, et al.
Nature Medicine|February 28, 2012
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALLGiusy Della Gatta, Teresa Palomero, Arianne Perez-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocolMarc R Mansour, Maria L Sulis, Veronique Duke, et al.
American Journal of Hematology|June 16, 2018
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experienceChezi Ganzel, Zhuoxin Sun, Larry D Cripe, et al.
Cancer Discovery|October 29, 2021
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic LeukemiaMarissa Rashkovan, Robert Albero, Francesca Gianni, et al.
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
American Journal of Hematology|October 9, 2019
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective studyYishai Ofran, Michal Hayun, Ronit Leiba, et al.
Haematologica|September 3, 2016
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemiaNicola Gökbuget, Hervè Dombret, Jose-Maria Ribera, et al.
Haematologica|November 24, 2018
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900Hugo F Fernandez, Zhuoxin Sun, Mark R Litzow, et al.
Pageof 28